Last reviewed · How we verify
Paclitaxel and ramucirumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Paclitaxel and ramucirumab (Paclitaxel and ramucirumab) — Hellenic Cooperative Oncology Group.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paclitaxel and ramucirumab TARGET | Paclitaxel and ramucirumab | Hellenic Cooperative Oncology Group | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paclitaxel and ramucirumab CI watch — RSS
- Paclitaxel and ramucirumab CI watch — Atom
- Paclitaxel and ramucirumab CI watch — JSON
- Paclitaxel and ramucirumab alone — RSS
Cite this brief
Drug Landscape (2026). Paclitaxel and ramucirumab — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-and-ramucirumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab